Business
Valeo Pharma Obtains Public Reimbursement for Redesca™ and Redesca Hp™ in Quebec
Valeo Pharma Obtains Public Reimbursement for Redesca™ and Redesca Hp™ in Quebec.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Obtains Public Reimbursement for Redesca™ and Redesca Hp™ in Quebec\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Obtains Public Reimbursement for Redesca™ and Redesca Hp™ in Quebec\nCanada NewsWire\nMONTREAL, Nov. 15, 2021\n\n\n\nPublic reimbursement coverage reaches 9 Provinces in Canada Canadian private health plan coverage now exceeding 90% MONTREAL, Nov. 15, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (\"PLA\") with Quebec Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP, its low molecular weight heparin (\"LMWH\") biosimilar for the prevention and treatment of thromboembolic disorders, on the Quebec RAMQ list of medications, effective November 10, 2021.  \n\n \n \n \n \n \n \n\n \n\"We are very pleased to report that we now have secured public reimbursement coverage for Redesca in 9 provinces across the country,\" said Frederic Fasano, Valeo's President and Chief Operating Officer. \"Biosimilars usage is rapidly growing throughout Canada and contributing to significant savings to provincial healthcare plans. With more than 8 years of proven in-market safety data internationally and a robust supply chain ensuring product availability, we expect Redesca to continue playing a major role in the achievement of our growth objectives\". \nAs previously disclosed, Redesca and Redesca HP are also currently listed for reimbursement under private payer health plans which currently represent more than 90% of privately covered lives accross Canada. \nAbout Redesca™, Redesca HP™ \nRedesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally. and more than 150 million patient days treated in Euro...